Litmus Implements Sixgill Integrity for Continuous Auditability
We recently announced that Litmus is partnering with Sixgill, LLC, the leader in sensor data services for governing Internet of Everything (IoE) assets, to adopt Sixgill Integrity. This will provide clinicians and researchers continuous auditability of their clinical data chain on the Litmus platform.
We’re excited to be working with a team that has exhaustive experience deploying solutions in this area.
Most importantly, we’re eager to introduce these capabilities to our customers.
Our end-to-end platform supports the entire trial process, from data collection at the point of experience to deep scientific analysis. Given the surface area that such a platform covers, we’ve made data governance a priority since the beginning. While our platform has always offered traceability and transparency for clinical trial data streams, new technologies have emerged, and so have new opportunities to enhance data authenticity and auditability.
Too often, data streams are opaque to researchers. Sixgill’s Integrity offering provides us with an opportunity to strengthen transparency beyond industry expectations, and to provide clinicians and researchers continuous auditability of their clinical data. Combined with our unique research-ready infrastructure for real life data, this partnership will enable us to fulfill customer desire for permanently traceable data authenticity.
The benefits of this implementation will provide clinicians and researchers using the Litmus platform with:
- One, consistent source of data quality and assurance
- Permanent, regulatory-grade auditability, traceability and certainty
- Streamlined quality and process automation
- Improved data security with tamper-proof, auditable logs of time-series data and near-real-time notification of changes
Above and beyond the specifics of the technology, we also think it’s important to acknowledge how this impacts our mission. We’re fond of saying that Litmus handles the engineering so you can focus on the science. As researchers and data scientists ourselves, we’re all too familiar with the heavy burden of data wrangling, let alone the ever-present backdrop of regulatory and compliance constraints that our customers are dealing with every day.
Collecting data at the point of experience is, and has always been, a key component of our work. But making that data viable for research and submission to the FDA is paramount. It distinguishes our platform from so many other technologies, and it accelerates adoption of novel endpoints. If you’re ready to incorporate real-life data into your observational study, therapeutic trial, or post-market research, then we’re ready for you.
